tbuckley/cabot-search huggingface dataset:
Voice-Controlled Devices for the Severely Disabled
Authors: Howard A. Rusk, Myron Youdin, G. Heiner Sell, Mario Clagnaz, Henry Louie
Journal: JAMA (1978)

MOBILITY and communication are fundamental in the rehabilitation of the severely disabled. Most persons with spinal cord dysfunction can live independent lives in a wheelchair, and even a quadriplegic with an intact neurologic segment at C-6 can be rehabilitated to be almost completely independent in all daily activities. Patients with higher levels of spinal cord dysfunction, however, remain dependent on help from others. It is for this reason and the fact that there have been a higher number of surviving high-level quadriplegics in the last few years that rehabilitation centers are using modern technology to improve the function of the severely disabled. New devices for the disabled are operated by means of sensitive microswitches, by movements of the tongue or chin, or by pneumatic control using positive or negative cheek pressures. All of these devices require a mechanical linkage of the patient with the equipment being used. Since a patient
rTPA: why do we waste these hundreds of millions of dollars?
Authors: S. Goldstein
Journal: JAMA (1991)

<h3>In Reply.</h3> — Morgan and Yaes both make good points. Morgan has identified an error in my editing and has interpreted my intentions correctly. Yaes correctly points out that each of us has different needs depending on whether we are acting as individuals or as members of society. The sentence he quotes was intended to set up precisely that paradox. As a literal statement, it is true that "society is nothing more than a collection of individuals." On the surface, this seems to imply that the interests of society and individuals should be identical. However, as Yaes states and as I described in the remainder of my article, the interests and responsibilities of individuals change when they are viewed as members of society. In the context of health care, our health is determined by two factors: what we can gain for ourselves if we act selfishly, without regard for the
Abstract A2-11: PLZF, a tumor suppressor genetically lost in metastatic castration resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy
Authors: Chen-Lin Hsieh, Ginevra Botta, Shuai Gao, Tiantian Li, Eliezer M. Van Allen, Daniel J. Treacy, Changmeng Cai, Housheng Hansen He, Christopher J. Sweeney, Myles Brown, Steven P. Balk, Peter S. Nelson, Levi A. Garraway, Philip W. Kantoff
Journal: Cancer Research (2015)

Abstract Whole exome sequencing of metastatic castration-resistant prostate cancer (mCRPC) reveal that 5~7% of tumors harbor promyelocytic zinc finger protein (PLZF) homozygous deletions. PLZF is a canonical androgen-regulated tumor suppressor gene whose expression is inhibited by androgen deprivation therapy (ADT). Here, we demonstrate that knockdown of PLZF expression promotes a CRPC and enzalutamide resistant phenotype in prostate cancer cells. Reintroduction of PLZF expression is sufficient to reverse androgen-independent growth mediated by PLZF depletion. PLZF loss enhances CRPC tumor growth in a xenograft model. Bioinformatic analysis of the PLZF cistrome shows that PLZF negatively regulates multiple pathways including the MAPK pathway. Accordingly, our data support an oncogenic program activated by ADT and this acquired mechanism together with the finding of genetic loss in CRPC implicate PLZF inactivation as a mechanism promoting ADT resistance and the CRPC phenotype. Citation Format: Chen-Lin Hsieh, Ginevra Botta, Shuai Gao, Tiantian Li, Eliezer M. Van Allen, Daniel J. Treacy, Changmeng Cai, Housheng Hansen He, Christopher J. Sweeney, Myles Brown, Steven P. Balk, Peter S. Nelson, Levi A. Garraway, Philip W. Kantoff. PLZF, a tumor suppressor genetically lost in metastatic castration resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy. [abstract]. In: Proceedings of the AACR Special Conference on Translation of the Cancer Genome; Feb 7-9, 2015; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2015;75(22 Suppl 1):Abstract nr A2-11.
Writing
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 3989: Identification of biomarkers for UM-164 in triple-negative breast cancer
Authors: Nathan M. Merrill, Nathalie M. Vandecan, John P. Lloyd, Eric J. Lachacz, Peter J. Ulintz, Sofia D. Merajver, Matthew B. Soellner
Journal: Cancer Research (2019)

Abstract Triple negative breast cancer (TNBC) is one of the deadliest forms of breast cancer due to limited treatment options beyond conventional chemotherapy. While making up approximately 10-20% of total breast cancer cases in the US, TNBC carries a serious burden of disease as it tends to be more aggressive, higher grade, and have a poorer prognosis than other forms of breast cancer. Though new therapies, such as PARP inhibitors, have shown promise in clinical trials in very select patients (e.g. BRCA1 mutation carriers), there is a general lack of predictive markers of therapeutic efficacy to identify subsets of patients most likely to positively respond to a given targeted or conventional therapy. Thus, there is a critical need for biomarkers of drug efficacy in TNBC to help design precision medicine clinical trials based on systematically derived predictive biomarkers. To fill this gap, we devised a strategy to identify biomarkers of drug efficacy in TNBC. As a paradigm of our approach, we treated a panel of 23 TNBC cell lines with our potent c-Src/p38 inhibitor, UM-164, and determined a drug sensitivity score (DSS) in each line. We then calculated correlations of DSS with a variety of molecular readouts, including RNA sequencing, reverse-phase protein array, DNA sequencing array, and Nanostring RNA and miRNA arrays. From these correlations, we have identified expression DJ1, MAPK11, and PCM1 as strong predictors of UM-164 efficacy in TNBC. Building on this, we used our results to identify companion drugs that lead to synergy or test others that could instead result in antagonism when used in combination. To verify our results, independently targeting the DJ1 pathway, we show that AKT inhibition results in synergy when combined with UM-164. The outcome of this research yields a robust and generalizable methodology for the identification of biomarkers in cancer to design Phase I-III trials and for generating the mechanistic evidence of effective rational combinations. Citation Format: Nathan M. Merrill, Nathalie M. Vandecan, John P. Lloyd, Eric J. Lachacz, Peter J. Ulintz, Sofia D. Merajver, Matthew B. Soellner. Identification of biomarkers for UM-164 in triple-negative breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3989.
Correction to: Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)
Journal: Circulation (2018)
Leishmania
Authors: Joan Stephenson
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Consensus conference. Drugs and insomnia. The use of medications to promote sleep
Journal: JAMA (1984)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Interferon's Track Record: Good in Hairy-Cell Leukemia, Fair in Other Hematologie Cancers, Poor in Solid Tumors
Journal: JAMA (1986)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
NEW INSTRUMENTS.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Forensics experts tackle task of identifying thousands of 'disappeared' victims
Authors: C. Raymond
Journal: JAMA (1989)

THIS SPRING, a team of medical students, aspiring archeologists, and forensic pathologists will be engaged in the unpleasant task of sifting through the skeletal remains of about 220 persons buried in a mass grave in Argentina. They are among the estimated 8 000 to 20 000 persons referred to as the "disappeared," victims of a wave of military-led torture in that country during the late 1970s and early 1980s. The original plan, which Clyde C. Snow, PhD, now admits was "grandiose," was to "dig up all 20 000 'disappeared' and identify them." Reality intervened. In a country just emerging from a wave of terror and lacking a legacy of independent forensic work, the goal of identifying enough victims to successfully prosecute their murderers has proved daunting enough. "The strategy now is to get one person positively identified and determine the cause of death," says Eric Stover. "We don't need to
New holographic process provides noninvasive, 3-D anatomic views
Authors: A. A. Skolnick
Journal: JAMA (1994)

A NEW holographic system for generating and displaying true-to-life, three-dimensional images of a patient's internal anatomy may help physicians make more accurate diagnoses and plan more effective treatment for a variety of clinical problems. Clinical uses of the system, which creates holographic images from digital data obtained by conventional computed tomographic (CT) or magnetic resonance (MR) scanners, were the subject of 10 scientific papers and exhibits at the 79th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), held in Chicago, Ill. According to clinical researchers who are using the new technology, the holograms, unlike conventional ones that show only the surface of objects, produce three-dimensional images that are accurate replicas of anatomic structures. The solid-appearing yet transparent replicas, which float in space several inches in front of the holographic film, can be studied, magnified, measured, reversed, or even merged with additional holograms that show relationships
Survival Rate Indicates Value of Cardiovascular Surgery for Infants
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
From the Food and Drug Administration
Authors: S. L. Nightingale
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Tetracycline and thyroid function
Authors: K. L. Becker
Journal: JAMA (1967)

Animal studies have suggested that tetracyclines may exert an antithyroid action, although reports have been contradictory.<sup>1-5</sup>The effect of tetracycline therapy on the human thyroid has not been investigated. Because of the obvious clinical importance of documenting any antithyroid effects in man, a study of thyroid function was undertaken before and following 11 consecutive days of tetracycline hydrochloride administration. <h3>Method and Materials</h3> Fourteen ambulatory male patient volunteers between the ages of 36 and 67 years were given 2 gm daily of tetracycline hydrochloride (Achromycin V) orally in four divided doses for a period of 11 days. Each patient served as his own control. Those patients selected were not acutely ill or debilitated, had no evidence of thyroid, renal or hepatic disease, or congestive heart failure, and had no recent intake of diagnostic or therapeutic iodides. Prior to tetracycline treatment, blood was drawn for duplicate protein-bound iodine (PBI) and cholesterol
Insect Stings
Authors: Robert E. Reisman
Journal: New England Journal of Medicine (1994)

Allergic reactions to insect stings are a common and often serious medical problem. Estimates of the incidence in the general population of anaphylaxis caused by insect stings over a specified period range from 0.3 to 3 percent13. Some episodes are fatal4. People at risk for anaphylaxis often make substantial changes in their lifestyles and are fearful of subsequent exposure to insects.Over the past 15 years, our understanding of the natural history of allergy to insect stings has grown, purified venoms have become available, and methods of measuring serum venom-specific IgE and IgG have been developed for . . .
AMA Specialty Journal Abstracts
Journal: JAMA (1986)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Catarrhal Vaccines
Authors: W. Attlee, M. Amsler, D. C. Beaumont
Journal: BMJ (1927)

STUDY OBJECTIVES: Data were analysed from a large national birth cohort to examine cumulative and interactive prediction from various risk factors for childhood middle ear disease, and to resolve conflicting evidence arising from small and incompletely controlled studies. The large sample size permitted appropriate covariate adjustment to give generality, and permit demographic breakdown of the risk factors. SETTING: A large multi-purpose longitudinal birth cohort study of all births in the UK in one week in 1970, with multiple questionnaire sweeps. PARTICIPANTS: Over 13,000 children were entered into the original cohort. Data on over 12,000 children were available at the five year follow up. MAIN OUTCOME MEASURES: For children at 5 years, parent reported data were available on health and social factors including data on two markers for middle ear disease: the occurrence of purulent (nonwax) ear discharge and suspected or confirmed hearing difficulty. MAIN RESULTS: In those children who had ever had reported hearing difficulty (suspected or confirmed), after control for socioeconomic status, three of the classic factors (male sex, mother9s smoking habits since birth, and attending day care) were significantly more frequent. In those who had ever had ear discharge reported, only mother9s smoking habit since birth was significantly more frequent. However, it showed an orderly dose response relation. In addition, a derived general child health score was found to be significantly associated with both the middle ear disease markers. Control for this variable in the analysis of those having reported hearing difficulty reduced the effect size of mother9s smoking habit, but it remained statistically significant. For reported ear discharge, even after control for the general health score and social index, mother9s smoking habits and day care attendance were both significant predictors. Mother9s (but not father9s) smoking habits and day care attendance were found to be significant risk factors for middle ear disease. Breast feeding effects were weak and did not generally survive statistical control. CONCLUSIONS: A child having all three risk factors (attends day care, a mother who smokes, and male sex) is 3.4 times more likely to have problems with hearing than a child who has none, based on cumulative risk. Further studies should focus on preventative risk modification and well specified intervention.